[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.233.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
August 2013

Implications for Biologic Therapy: Staphylococcus aureus Decolonization of Individuals With a History of Recurrent Skin and Soft-Tissue Infections

Author Affiliations
  • 1Department of Ophthalmology, Oregon Health and Science University, Portland
  • 2Department of Dermatology, Oregon Health and Science University, Portland
  • 3Department of Medicine, Oregon Health and Science University, Portland
  • 4Division of Infectious Diseases, Oregon Health and Science University, Portland
  • 5Division of Arthritis and Rheumatic Disease, Oregon Health and Science University, Portland
JAMA Dermatol. 2013;149(8):986-989. doi:10.1001/jamadermatol.2013.4405

Patients with immune-mediated inflammatory diseases (IMIDs) are at an increased risk for skin and soft-tissue infections (SSTIs),1 presumably owing to colonizing organisms like Staphylococcus aureus.1 Although few organism-level data are available by which to judge whether these agents increase the risk of S aureus infection specifically, biologic therapies widely used to treat IMIDs have been shown to increase the risk of SSTIs and other serious infections, complicating therapeutic management of IMIDs.2,3 Although staphylococcal decolonization therapy has been used in various health care settings, no description of such therapy exists for patients with IMIDs with recurrent SSTIs on biologic therapies. For those patients with recurrent infections thought to be due to S aureus, decolonization could theoretically provide protection against subsequent infection.

×